Research programme 04

Diagnostics and therapeutic translation

We develop isoform-specific tools and apply them to cancer predisposition, biomarker development and therapeutic strategies.

This programme develops the enabling technologies for isoform-resolved p53 biology, including antibodies, experimental protocols and defined models.

Translational directions include broader cancer genetics, liquid-biopsy concepts and strategies that use p53-isoform biology to improve engineered antitumour T cells.

Model for the impact of different p53 isoforms on POLι-dependent DDT.

Approaches

Isoform-specific antibody development
Liquid-biopsy concepts
Engineered immune-cell models
Translational assay development

Selected work

Δ133p53α enhances TCR-engineered T-cell fitness (2021)
p53 isoforms and DNA-damage tolerance (2021)
Germline p53β variant and familial cancer (2024)

Return to all research →